Loading...
•
Dec 31, 2019
Lexicon Pharmaceuticals Q4 2019 Earnings Report
Lexicon Pharmaceuticals reported fourth quarter and full-year 2019 financial results and provided a business update.
Key Takeaways
Lexicon Pharmaceuticals reported a decrease in revenues for the fourth quarter to $8.7 million from $17.1 million for the corresponding period in 2018, primarily due to lower revenues recognized under collaboration and license agreements. Net loss for the fourth quarter was $51.1 million, or $0.48 per share, as compared to a net loss of $16.8 million, or $0.16 per share, in the corresponding period in 2018.
XERMELO U.S. net sales were $31.0 million in 2019.
Lexicon completed a safety review of the initial safety run-in cohort of The Telotristat Ethyl for Advanced Biliary Tract Cancer study.
Lexicon announced topline data from the Phase 3 SOTA-EMPA study of sotagliflozin in type 2 diabetes.
Lexicon announced positive topline Phase 1 data for LX9211 in a multiple ascending dose study in healthy volunteers.
Revenue by Segment
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...